German drugmaker Boehringer Ingelheim has its first regulatory approval ... AstraZeneca and Ionis add an EU green light to earlier approvals in the US and UK for ATTR polyneuropathy drug Wainzua ...

Hyderabad (Telangana) [India], February 6: Boehringer Ingelheim India has signed a Memorandum of Understanding (MoU) with Hyderabad-based EMRI Green Health Services a GVK enterprise, the operator ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Spiriva capsules contain 18 mcg of tiotropium and are light green, with the Boehringer Ingelheim company logo on the Spiriva capsule cap and TI 01 on the Spiriva capsule body, or vice versa.

Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...

Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries. November 22 ...

Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp. for dual ...

Onsite at the Boehringer Ingelheim R&D centre in Biberach ... AstraZeneca and Ionis add an EU green light to earlier approvals in the US and UK for ATTR polyneuropathy drug Wainzua, a potential ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...